Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Regulatory decisions pertaining to aprotinin may be putting patients at risk
22
Zitationen
11
Autoren
2014
Jahr
Abstract
The antifibrinolytic agent aprotinin, a naturally occurring serine protease inhibitor, was removed from the worldwide market in October 2007.[1][1] Aprotinin and two other antifibrinolytic agents (the lysine analogues tranexamic acid and aminocaproic acid) had been used in cardiac surgery to
Ähnliche Arbeiten
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 5.187 Zit.
Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial
2010 · 3.209 Zit.
Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma
2015 · 2.393 Zit.
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
1999 · 2.044 Zit.
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
1987 · 2.019 Zit.